|
Basic Characteristics of Mutations
|
|
Mutation Site
|
T108I |
|
Mutation Site Sentence
|
In vitro resistance selection experiments with JNJ-1A induced mutation T108I in non-structural protein 4B (NS4B), pointing towards a mechanism of action linked to this protein. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
NS4B |
|
Standardized Encoding Gene
|
NS4B
|
|
Genotype/Subtype
|
DENV-2 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cell line
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
JNJ-1A |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
29037976
|
|
Title
|
Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library
|
|
Author
|
Hernandez-Morales I,Geluykens P,Clynhens M,Strijbos R,Goethals O,Megens S,Verheyen N,Last S,McGowan D,Coesemans E,De Boeck B,Stoops B,Devogelaere B,Pauwels F,Vandyck K,Berke JM,Raboisson P,Simmen K,Lory P,Van Loock M
|
|
Journal
|
Antiviral research
|
|
Journal Info
|
2017 Nov;147:149-158
|
|
Abstract
|
Dengue is the most important mosquito-transmitted viral disease and a major global health concern. Over the last decade, dengue virus (DENV) drug discovery and development has intensified, however, this has not resulted in approved DENV-specific antiviral treatments yet. DENV and hepatitis C virus (HCV) belong to the same Flaviviridae family and, in contrast to DENV, antiviral treatments for HCV have been licensed. Therefore, applying the knowledge gained on anti-HCV drugs may foster the discovery and development of dengue antiviral drugs. Here, we screened a library of compounds with established anti-HCV activity in a DENV-2 sub-genomic replicon inhibition assay and selected compounds with single-digit micromolar activity. These compounds were advanced into a hit-to-lead medicinal chemistry program resulting in lead compound JNJ-1A, which inhibited the DENV-2 sub-genomic replicon at 0.7 muM, in the absence of cytotoxicity. In addition, JNJ-1A showed equipotent antiviral activity against DENV serotypes 1, 2, and 4. In vitro resistance selection experiments with JNJ-1A induced mutation T108I in non-structural protein 4B (NS4B), pointing towards a mechanism of action linked to this protein. Collectively, we described the discovery and characterization of a novel DENV inhibitor potentially targeting NS4B.
|
|
Sequence Data
|
-
|
|
|